汉商集团公告称，公司股票在2026年1月16日、19日、20日连续3个交易日内收盘价格涨幅偏离值累计超 20%，属异常波动。经自查，公司日常经营、重大事项等均无重大变化，异常波动期间控股股东等无买 卖公司股票情况。公司提示市场交易、重大事项进展及控股股东股票质押风险。控股股东卓尔控股及其 一致行动人阎志合计持股92,594,710股，占总股本31.38%，累计质押30,540,000股，占合计持股 32.98%，占总股本10.35%，当前无平仓风险。 ...

Core Viewpoint - Guizhou BaiLing, a leading company in the herbal medicine sector, faces significant penalties for financial fraud, including a fine of 10 million yuan for the company and 5 million yuan for its chairman, Jiang Wei, who is also banned from the market for 10 years [2][3][4]. Group 1: Financial Misconduct - The company reported false financial records in its annual reports from 2019 to 2021 and 2023, leading to a cumulative profit inflation of 655 million yuan due to underreporting sales expenses [3][4]. - In 2023, the company overstated sales expenses, resulting in a profit reduction of 459 million yuan [4]. Group 2: Control Dispute - Guizhou BaiLing is embroiled in a control dispute, with major shareholder Jiang Wei and his associates facing a lawsuit from Huachuang Securities for the return of 1.761 billion yuan in loans and interest [5][7]. - The lawsuit stems from a complex seven-year struggle related to a financial rescue plan and stock pledges initiated in late 2018 [5]. Group 3: Financial Rescue Plan - Huachuang Securities provided 1.4 billion yuan in rescue funds and 361 million yuan in stock pledge financing to Jiang Wei, acquiring a total of 11.43% of Guizhou BaiLing's shares [7][12]. - The rescue plan included multiple agreements, with fixed and floating returns based on the performance of the shares held by Huachuang Securities [13][14]. Group 4: Share Price Decline - Guizhou BaiLing's stock price has significantly declined from 9 yuan per share to 5.63 yuan, resulting in a market capitalization drop from over 50 billion yuan to 7.9 billion yuan [33]. Group 5: Corporate Governance Issues - The ongoing legal disputes and financial issues have raised concerns about the company's governance structure, with suggestions for restructuring the board to ensure balanced control [29][30].

海南瑞泽公告称，公司股票在2025年12月16 - 18日连续三个交易日内日收盘价格跌幅偏离值累计达 20%，属异常波动。经自查，公司前期信息无更正补充，未现重大未公开信息，经营及环境无重大变 化，实控人无应披露重大事项，异常波动期间实控人未买卖股票。另外，副总经理于清池已完成减持 23.1万股计划。截至公告披露日，实控人及其一致行动人质押比例高，存在质押逾期、司法冻结及平 仓、司法拍卖风险。 ...

Core Viewpoint - Huachuang Securities, a subsidiary of Huachuang Yunxin, is involved in a legal dispute with major shareholder Jiang Wei of Guizhou Bailing Pharmaceutical Group regarding a financial rescue plan and stock pledge issues [1][2]. Group 1: Legal Proceedings - Huachuang Securities has filed lawsuits against Jiang Wei and his associates to recover 1.4 billion yuan (approximately 14 billion) from the rescue plan and 361 million yuan (approximately 3.61 billion) from stock pledge loans [2]. - The lawsuits also seek additional payments for fixed income, penalties, and other litigation-related costs [2]. Group 2: Financial Details - The rescue plan involved Huachuang Securities providing 1.4 billion yuan in funding through two asset management plans, acquiring 161 million shares of Guizhou Bailing, which represents 11.54% of the total share capital [1]. - Jiang Wei also pledged an additional 78 million shares and properties valued at approximately 1.143 billion yuan as collateral for the rescue plan [2]. - For the stock pledge loan, Jiang Wei provided additional collateral valued at approximately 263 million yuan [2]. Group 3: Company Status - Guizhou Bailing is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing [2]. - Jiang Wei is identified as the largest shareholder and actual controller of Guizhou Bailing, serving as the chairman of the company [2].